In the latest episode of the “Pharmacy Friends” podcast, join health outcomes experts for a discussion about Prime’s industry-leading research into persistence and adherence of glucagon-like...

Novo Nordisk’s semaglutide (Wegovy) recently received a U.S. Food and Drug Administration (FDA) accelerated approval for treating metabolic dysfunction-associated steatohepatitis (MASH), the first...

Leading GLP-1 persistence, adherence and clinical outcomes research helps inform health plans and members

publications Quarterly Drug Pipeline: July 2025 Clinical insights and competitive intelligence on anticipated drugs in development July 31, 2025 Editor-in-chief's message Welcome to Prime...